HomeGeneticsGeneCLN8 gene
Back to Gene
CLN8 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

CLN8 gene

The CLN8 gene provides instructions for a protein thought to play a transport role within cells, with mutations linked to varying forms of CLN8 disease.

Normal Function

The CLN8 gene provides instructions for a protein whose precise function is not known but is thought to play a transport role. The CLN8 protein likely helps move materials in and out of the endoplasmic reticulum, which is involved in protein production, processing, and transport. It may also help the endoplasmic reticulum regulate levels of fats (lipids) in cells. In certain cells, such as nerve cells, the protein is thought to be active outside of the endoplasmic reticulum.

Health Conditions Related to Genetic Changes

CLN8 disease

At least 25 mutations in the CLN8 gene have been found to cause CLN8 disease, an inherited disorder that varies in severity and primarily affects the nervous system.

  • Less-severe form: Characterized by recurrent seizures (epilepsy) and intellectual decline beginning between ages 5 and 10. Individuals often live into late adulthood.
  • More-severe form: Involves a gradual worsening of motor and cognitive skills, epilepsy, and vision loss. Symptoms typically appear between ages 2 and 7, and individuals usually survive only into late childhood or adolescence.

A specific mutation (Arg26Gly) is found in all individuals from a northern region of Finland who have the less-severe form, likely resulting in a protein with reduced function. In the more-severe form, mutations likely drastically reduce protein function or impair its transport to the endoplasmic reticulum. This leads to the accumulation of proteins and other substances in lysosomes, causing nerve cell death and the neurological symptoms characteristic of the disease.

Frequently Asked Questions

CLN8 disease is inherited in an autosomal recessive pattern. This means that a child must inherit two copies of a mutated CLN8 gene (one from each parent) to develop the condition. If a child is diagnosed, both parents are typically carriers of one mutated gene copy. For each subsequent pregnancy, if both parents are carriers, there is a 25% chance the child will have CLN8 disease, a 50% chance the child will be a carrier, and a 25% chance the child will not have the disease and not be a carrier. Genetic counseling is highly recommended for families to understand these risks.
Currently, there is no cure for CLN8 disease, so treatment focuses on managing symptoms and providing supportive care to improve quality of life. This often includes anti-epileptic medications to control seizures, physical and occupational therapy to help maintain motor skills and independence, and speech therapy for communication difficulties. Educational support and adaptive equipment may also be necessary. Regular monitoring by a neurologist and other specialists is crucial to address evolving symptoms.
Specific genetic mutations in the CLN8 gene can significantly influence the severity and prognosis of the disease. For instance, the Arg26Gly mutation, commonly found in individuals from a specific northern region of Finland, is associated with the less-severe form of CLN8 disease, where individuals experience epilepsy and intellectual decline but often live into late adulthood. Other mutations, particularly those that drastically reduce protein function or impair its transport, are linked to the more-severe form with earlier onset, rapid progression, and a shorter life expectancy. Genetic testing can help predict the likely course of the disease based on the identified mutation.
The onset and progression of symptoms differ between the two forms. In the less-severe form, symptoms typically begin between ages 5 and 10, primarily with recurrent seizures (epilepsy) and a gradual decline in intellectual abilities. Children often live into late adulthood. The more-severe form usually presents earlier, between ages 2 and 7, with a more rapid and pronounced worsening of motor skills, cognitive abilities, epilepsy, and vision loss. Individuals with the more-severe form typically survive only into late childhood or adolescence. Observing the age of onset and the specific combination and severity of symptoms can help differentiate the forms.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss